Enlivex Therapeutics (ENLV) Institutional Ownership $0.96 +0.00 (+0.20%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Enlivex Therapeutics (NASDAQ:ENLV)CurrentInstitutional OwnershipPercentage1.02%Number ofInstitutional Buyers(last 12 months)7TotalInstitutional Inflows(last 12 months)$3.43MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$413.37K Get ENLV Insider Trade Alerts Want to know when executives and insiders are buying or selling Enlivex Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ENLV Institutional Buying and Selling by Quarter Enlivex Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/19/2025 Jane Street Group LLC80,759$78K0.0%+527.4%0.341% 5/15/2025 Armistice Capital LLC1,781,931$1.73M0.0%-19.3%7.534% 2/17/2025 Millennium Management LLC633,847$742K0.0%N/A2.961% 2/14/2025 Two Sigma Securities LLC22,362$26K0.0%N/A0.104% 2/13/2025 Renaissance Technologies LLC158,992$186K0.0%+112.6%0.743% 10/23/2024 Sigma Investment Counselors Inc.30,000$50K0.0%N/A0.140% 8/15/2024 Armistice Capital LLC1,700,571$2.42M0.0%N/A8.148% 8/12/2024 XTX Topco Ltd24,820$35K0.0%N/A0.119% 5/1/2023 Compagnie Lombard Odier SCmA65,000$225K0.0%+30.0%0.350% 2/9/2023 Group One Trading L.P.13,499$53K0.0%+2,689.0%0.073% Get the Latest News and Ratings for ENLV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/11/2022 ARK Investment Management LLC331,001$1.66M0.0%-23.8%1.802% 4/27/2022 Compagnie Lombard Odier SCmA50,000$279K0.0%+16.3%0.273% 4/20/2022 Belvedere Trading LLC14,473$101K0.0%-13.9%0.079% 4/19/2022 ARK Investment Management LLC434,343$2.43M0.0%+24.3%2.372% 2/9/2022 Compagnie Lombard Odier SCmA43,000$247K0.0%+22.9%0.235% 2/3/2022ACT Capital Management LLC25,000$156K0.1%-69.7%0.137% 1/28/2022 ARK Investment Management LLC349,308$2.18M0.0%-23.7%1.908% 1/21/2022Golden Green Inc.19,967$125K0.1%-54.7%0.109% 11/12/2021 Renaissance Technologies LLC87,989$869K0.0%-55.0%0.481% 10/28/2021 Compagnie Lombard Odier SCmA35,000$353K0.0%+40.0%0.191% 10/8/2021Golden Green Inc.44,085$436K0.3%-4.2%0.241% 8/13/2021 Renaissance Technologies LLC195,706$1.74M0.0%-32.6%1.242% 8/11/2021 Banque Cantonale Vaudoise10,000$89K0.0%N/A0.063% 8/5/2021 ARK Investment Management LLC514,807$4.58M0.0%+8.1%3.267% 7/17/2021Golden Green Inc.46,020$410K0.3%-34.1%0.292% 5/18/2021 Jane Street Group LLC11,070$123K0.0%N/A0.070% 5/17/2021 Edmond DE Rothschild Holding S.A.13,000$144K0.0%N/A0.082% 5/17/2021 Goldman Sachs Group Inc.12,986$144K0.0%N/A0.082% 5/13/2021 ARK Investment Management LLC476,414$5.28M0.0%N/A3.023% 5/13/2021 Renaissance Technologies LLC290,406$3.22M0.0%+4.0%1.843% 5/12/2021 UBS Group AG10,872$120K0.0%-51.5%0.069% (Data available from 1/1/2016 forward) ENLV Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ENLV shares? During the previous two years, the following institutional investors and hedge funds held shares of Enlivex Therapeutics shares: Armistice Capital LLC ($1.73M), Millennium Management LLC ($742K), Renaissance Technologies LLC ($186K), Jane Street Group LLC ($78K), Sigma Investment Counselors Inc. ($50K), and XTX Topco Ltd ($35K), and Two Sigma Securities LLC ($26K).Learn more on ENLV's institutional investors. What percentage of Enlivex Therapeutics stock is owned by institutional investors? 1.02% of Enlivex Therapeutics stock is owned by institutional investors. Learn more on ENLV's institutional investor holdings. Which institutional investors have been buying Enlivex Therapeutics stock? The following institutional investors have purchased Enlivex Therapeutics stock in the last 24 months: Armistice Capital LLC ($1.70M), Millennium Management LLC ($633.85K), Renaissance Technologies LLC ($84.20K), Jane Street Group LLC ($67.89K), Sigma Investment Counselors Inc. ($30K), XTX Topco Ltd ($24.82K), and Two Sigma Securities LLC ($22.36K). How much institutional buying is happening at Enlivex Therapeutics? Institutional investors have bought a total of 2,563,689 shares in the last 24 months. This purchase volume represents approximately $3.43M in transactions. Which Enlivex Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Enlivex Therapeutics stock in the last 24 months: Armistice Capital LLC ($426.07K). How much institutional selling is happening at Enlivex Therapeutics? Institutional investors have sold a total of 426,069 shares in the last 24 months. This volume of shares sold represents approximately $413.37K in transactions. Related Companies XBIT Institutional Ownership ENTX Institutional Ownership IVVD Institutional Ownership CHRS Institutional Ownership CRDL Institutional Ownership IMUX Institutional Ownership ZNTL Institutional Ownership KYTX Institutional Ownership ORMP Institutional Ownership ANIX Institutional Ownership This page (NASDAQ:ENLV) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENLV Stock Free ENLV Stock Alerts